Weekly paclitaxel plus cetuximab reduces the lung metastasis of adenoid cystic carcinoma arising from the salivary gland  by Yoshioka, Yukio et al.
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Adenoid  cystic  carcinoma  (ACC)  of  the  salivary  gland  often  metastasizes  to the lungs.  It has  previously
been  reported  that  the  combination  chemotherapy  of  weekly  paclitaxel  plus  cetuximab  is  effective  for
the  treatment  of lung  metastasis  from  ACC  of the  salivary  gland.  Here,  we  report  a case  in which  a  regimenccepted 11 April 2015
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of  this  combination  therapy  provided  an antitumor  treatment  for  lung  metastatic  ACC arising  from  the
minor  salivary  gland  of the hard  palate.
©  2015  Japanese  Stomatological  Society.  Published  by Elsevier  Ltd.  All  rights  reserved.etuximab
. Introduction
Adenoid cystic carcinoma (ACC) of the salivary gland presents
ith an aggressive clinical course that frequently results in local
ecurrence and distant metastasis [1–3]. Almost 50% of patients
iagnosed with ACC of the salivary gland present with concurrent,
ndolent metastasis to the lungs at the time of their initial hospi-
al visit or during surveillance after surgery [1]. Five-year survival
ates between 64% and 85% are possible for most patients with
CC that has been appropriately resected, even after the develop-
ent of lung metastasis; however, the 20-year survival rate among
atients with metastatic ACC of the salivary gland is only 12.5%
1,2]. Therefore, favorable overall survival (OS) is achieved not only
y optimal resection of the primary tumor but also through the
ontrol of recurrent or metastatic lesions. There are currently no
ffective chemotherapy regimens for the treatment of ACC lung
etastasis, possibly because this disease is relatively rare and it
as not been thoroughly studied. The conventional chemotherapy
egimen of combined cyclophosphamide (CPA), adriamycin (DXR),
nd cisplatin (CDDP) has a response rate (complete response plus
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acial  Surgery, Applied Life Sciences, Institute of Biomedical and Health Sciences,
iroshima  University, Kasumi 1-2-3, Minami-ku, Hiroshima 734-8553, Japan.
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ttp://dx.doi.org/10.1016/S1348-8643(15)00019-1
348-8643/© 2015 Japanese Stomatological Society. Published by Elsevier Ltd. All rights rpartial response) of no more than 27% for ACC recurrences and dis-
tant metastases [3]. Other antitumor agents (e.g., vinorelbine plus
CDDP) have also been associated with little success, and they are
increasingly toxic for patients [3].
Cetuximab, a chimeric monoclonal antibody that recognizes
epidermal growth factor receptor (EGFR), is effective in the treat-
ment of K-RAS wild-type adenocarcinoma of the colon and head
and neck squamous cell carcinoma (HNSCC). The results of the
phase III EXTREME trials showed that platinum/5-ﬂuorouracil
(FU)/cetuximab for recurrent/metastatic HNSCC was associated
with a better response rate and a longer median OS than
platinum/5-FU (36% and 10.1 months vs. 20% and 7.4 months,
respectively) [4]. Therefore, the platinum/5-FU/cetuximab regimen
became a ﬁrst-line treatment for recurrent/metastatic HNSCC in
both Japan and the United States. Approximately, 85% of primary
ACCs express EGFR. Accordingly, cetuximab may also be an effective
treatment for ACC [5].
Paclitaxel  (PTX) exerts its antitumor effect by inhibiting mitosis
in tumor cells through the binding of beta-tubulin and the stabiliza-
tion of microtubular structures. Subsequent arrest of the cells in the
G2/M phase of the cell cycle results in apoptosis. A phase II clinical
trial conducted by the Eastern Cooperative Oncology Group (ECOG)
[6] enrolled 45 patients with locally recurrent or metastatic sali-
vary gland tumors who  were treated with PTX (200 mg/m2) alone
on a 21-day schedule. In this trial, PTX alone was  determined to
be ineffective in the treatment of ACC because no responses were
observed among the 14 enrolled patients with ACC. However, a
eserved.
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Fig. 2. Computed tomography (CT) scans show the primary hard palate tumor. The
high-contrast tumor almost occupies the entire right palate and extends to the
pterygoid process.Fig. 1. Intraoral photograph at the initial visit shows the mass on the right palate.
ase report published 2 years after the ECOG trial noted that two
atients with ACC lung metastasis had responded favorably to PTX
reatment [7]. This case report indicated that PTX might be useful
or the treatment of metastatic ACC.
Caballero et al. reported a single case in which weekly PTX
80 mg/m2) plus cetuximab (450 mg/m2 for the ﬁrst week and
50 mg/m2 for the next 6 weeks) was effective for the treatment
f metastatic ACC after weekly PTX (80 mg/m2) alone had failed
o show any response [8]. They suggested that primary resistance
o PTX could be reversed by the addition of cetuximab. To the
est of our knowledge, this was the ﬁrst report of an effective
ombination chemotherapy for metastatic ACC treated with cetux-
mab. In December 2012, cetuximab was newly approved as a
olecular-targeting drug for HNSCC in Japan. Combination ther-
py with cetuximab was expected to produce fewer adverse events
han therapy with conventional cytotoxic drugs. Here, we  present
 case in which the antitumor effects of weekly PTX plus cetuximab
ere evident for lung metastasis of ACC.
. Case report
A  34-year-old woman was referred to our hospital with swelling
f the hard palate in December 2011. Initial intraoral ﬁnding
howed a hard mass to the midline from the right side of the hard
alate (Fig. 1). The mass was approximately 35 mm in diameter and
overed with normal mucosa. Computed tomography (CT) exami-
ation of the head and neck (Fig. 2) showed that the high-contrast
umor almost occupied the entire right palate and extended to the
terygoid process. She was diagnosed with a malignant tumor of
he hard palate, for which she underwent an incisional biopsy. The
istopathologic features of the specimen revealed solid-type ACC
Fig. 3). Finally, she was diagnosed with ACC (T4bN0M0) on positron
mission tomography/CT (PET/CT) examination. We  proposed both
adical resection and heavy ion radiotherapy to her. She hoped to
eceive heavy ion radiotherapy because the disorder of oral and
haryngeal function after surgery would be severe. She received
arbon-ion beam radiotherapy (65 Gy) at the Hyogo Ion Beam Med-
cal Center in March 2012 to treat the primary hard palate tumor.
n July 2012, a CT scan revealed multiple asymptomatic, small nod-
les in the lung. Following this, a single metastatic lymph node at
he right submaxillar region was detected only 2 months later. We
ere of the opinion that the neck dissection should be performed to
rolong the rest of her life considering its rapid growth. Supraomo-
yoid neck dissection containing the submaxillar metastatic lymph
ode was performed prior to treatment of the remote lesions.
fter surgery, we suggested immediate chemotherapy treatment
or the lung metastasis because the rapid progression of this remote
esion was expected; however, the patient did not receive thisFig. 3. The histopathological features of the biopsy specimen reveal the solid-type
adenoid  cystic carcinoma.
suggestion immediately. CT scans revealed increases in the number
of small nodules in the lungs, as well as bilateral pleural effusion
with exacerbation of pleural dissemination in the left lung (Fig. 4).
We proposed two  regimens of chemotherapy, as follows: com-
bined CPA and DXR with CDDP or a molecular-targeted agent such
as cetuximab combined with PTX. Simultaneously, we  explained
the adverse events and response rates that could be expected. Both
regimens were approved by the chemotherapy committee of the
Hiroshima University Hospital. The former would have required
admission to the hospital and inpatient treatment. The patient
hoped to receive outpatient treatment because the repeated heavy
treatments had left her mentally tired. Although we suggested the
former regimen because its efﬁcacy was supported by some clin-
ical evidence, the patient selected the latter regimen because she
Y. Yoshioka et al. / Oral Science International 12 (2015) 67–71 69
Fig. 4. Prior to treatment, computed tomography scans show numerous small nod-
ules, pleural effusion, and pleural dissemination in the lungs.
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Fig. 6. Immunohistochemical examination reveals that metastatic adenoid cystic
carcinoma expresses stathmin.
administration of low-dose steroids, and her pulmonary symptomsig. 5. Immunohistochemical examination reveals that adenoid cystic carcinoma
etastasis  to the cervical lymph nodes is positive for epidermal growth factor
eceptor.
eared some of the severe adverse events that could be associated
ith the former regimen. Before the administration of cetuximab,
e examined the patient for the expression of EGFR and K-RAS
utations. The specimen obtained from neck dissection was used
or both of the screening tests. Immunohistochemical staining was
ositive for EGFR (Fig. 5). Furthermore, direct sequencing (checking
odons 12 and 13 (exon 2)) revealed that she harbored wild-type K-
AS, which was the same as companion diagnostics for colon cancer.
he expression of stathmin was also examined immunohistochem-
cally, and it was positive for the present case (Fig. 6).
Following these investigations, systemic chemotherapy was ini-
iated in August 2013. Her Karnofsky performance status was 70%
t that time. At ﬁrst, 80 mg/m2 of PTX was administered per week,
ontemporaneously with 400 mg/m2 of cetuximab per week. She
as administered 80 mg/m2 of weekly PTX plus 250 mg/m2 of
etuximab from the next week. We  planned to perform two  courses
one course = four doses) to evaluate the antitumor effect of these
rugs. We  suspected that this combination therapy would produce
eukocytopenia and a severe skin disorder. The patient experienced
 high-grade rash (CTCAE Grade2; Common Terminology Criteria
or Adverse Event version4.0) on her face, back, and legs a few days
fter the ﬁrst administration of 400 mg/m2 of cetuximab. Follow-
ng the amelioration of the rash, she continued to receive 80 mg/m2
f weekly PTX plus 250 mg/m2 of cetuximab for ﬁve doses.Fig. 7. Following treatment, computed tomography scans show an effective
response  to the combination of cetuximab and paclitaxel chemotherapy.
Leukocytopenia (1570/mm3 CTCAE Grade3) was observed after the
ﬁfth administration. After six metronomic doses of these two drugs,
CT scans showed the disappearance of the pleural effusion and
pleural dissemination, as well as a decrease in the number of nod-
ules in the lungs (Fig. 7). The patient was simultaneously free from
cough, chest pain, and dyspnea. Considering both the image of the
CT scan and the amelioration of her clinical symptom, this combi-
nation chemotherapy exerted an antitumor effect for the present
case. After 3 weeks, the patient started to receive the same regimen,
and was administered these two  drugs weekly for three doses. In
January 2014, the patient often experienced fever, dyspnea dur-
ing motion, and decreased oxygen saturation. She was  suspected
of having either drug-induced pneumonitis or carcinomatous lym-
phangiosis. Her bronchoalveolar lavage ﬂuid was examined using
a bronchoalveolar lavage procedure, and steroid pulse therapy was
performed to conﬁrm the diagnosis. Steroid pulse therapy consisted
of the administration of high steroid doses (methylprednisolone
sodium succinate; 1000 mg)  intravenously for three consecutive
days. However, it was not as successful and effective for the present
case. Therefore, the patient was  ﬁnally diagnosed with carcinoma-
tous lymphangiosis.
Following steroid pulse therapy, she received continuous oralimproved slightly. Subsequently, the combination therapy of PTX
and cetuximab was completed in three courses (a total of nine
doses; one course = three doses) over 5 months (Fig. 8) because the
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iig. 8. The administration schedule of weekly PTX plus cetuximab. The black squ
ndicate that the two  drugs were skipped.
ung lesion was judged to meet the criteria for progressive disease.
hereafter, she received the best supportive care, including pallia-
ive care, to reduce pain and dyspnea. She ﬁnally died of respiratory
ailure in April 2014, although there had not been any recurrence
f the primary lesion.
.  Discussion
Caballero et al. published the ﬁrst report of the successful
reatment of metastatic ACC with the combination of a molecular-
argeting agent, cetuximab, and a cytotoxic drug, PTX [8]. More
peciﬁcally, their report concerns a case of metastatic ACC of the
alivary gland. To date, there has been no subsequent, success-
ul report of this treatment; however, we administered the same
ombination chemotherapy that was described by Caballero et al.,
btaining good results for metastatic ACC of the salivary glands.
ACC  of the salivary glands frequently metastasizes to the lung,
ven if the primary lesion is well controlled. Most remote lesions
re chemoresistant because their growth rates are generally slow
lthough some cases show rapid growth (such as the present
ase) [9]. In 2006, Gilbert et al. reported the results of a phase II
rial of single-agent chemotherapy with PTX for various salivary
land malignancies [6]; however, none of the 14 patients with ACC
reated with PTX showed a response to this agent, and 50% had
table disease (at best). In 2009, Locati et al. reported that a single
ose of cetuximab also resulted in no objective response for recur-
ent or distant metastasis of ACC [10]. Twenty of the 23 patients
ith ACC treated with cetuximab showed only stable disease, and
n OS of >6 months was only observed in 12 of these patients. A
ingle dose of neither PTX nor cetuximab was effective for recur-
ent or metastatic ACC [3]. Incidentally, a combination therapy of
latinum-based agents and cetuximab showed an antitumor effect
or HNSCC, and it is likely to be suggested as the gold-standard regi-
en  for recurrent/metastatic HNSCC. These studies set a precedent
or the combination of other cytotoxic agents with cetuximab and
heir potential use for recurrent/metastatic ACC.
Holsinger et al. reported that, in a murine model, EGFR blockade
auses apoptosis through G1 arrest of oral squamous carcinoma
ells treated with PTX, rendering them more susceptible to con-
omitant cytotoxic agents such as PTX (as reported here) [11]. The
ytotoxicity of PTX may  be a consequence of the high susceptibil-
ty of tumor cells arrested at the G1 restriction point, even whennd circles indicate that two  drugs were actually administrated. The white circles
PTX  is administered at a low dose. However, this theory does not
imply that the antitumor effect of these two  agents is synergistic.
Instead, the authors insisted that the EGFR blockade only potenti-
ated the cytotoxicity of PTX, based on an analysis of the isobologram
of both agents [11]. On the other hand, based on a preclinical exper-
iment, Morelli et al. suggested that the antitumor effect of the two
agents is synergistic, and it depends on the treatment schedule
[12]. They insisted that the EGFR blockade not only kills cancer
cells but also affects the cell-cycle distribution of the surviving can-
cer cells, which are accumulated in the G2/M phases of the cell
cycle. The consecutive administration of the EGFR inhibitor follow-
ing the cytotoxic agents could therefore represent a more effective
approach to the combination of cytotoxic agents with an EGFR-
targeting agent [12]. We  believe that there may  be some kind of
molecular link between the target molecule of PTX and the down-
stream molecules of the signal transduction of EGFR.
It  is not clear why PTX is more effective for metastatic ACC than
any other anticancer agents. Stathmin is a microtubule-associated
intracellular protein that regulates the dynamics of microtubule
polymerization and depolymerization; therefore, it is an impor-
tant molecular target for cancer therapy because of its role in tumor
cell proliferation, migration, and invasion. Nakashima et al. showed
that ACC cells in a xenograft model exhibited upregulation of stath-
min  [13]. Wu et al. demonstrated that stathmin expression was
suppressed by PTX treatment, with concomitant enhanced micro-
tubule polymerization [14]. Therefore, we tentatively propose that
stathmin may  be related to the effect of PTX combined with cetux-
imab.
In summary, PTX plus cetuximab treatment provided antitu-
mor activity against our patient’s aggressive and metastatic ACC.
A recent phase II trial of the combination of these two drugs has
only been performed in patients with recurrent/metastatic HNSCC
[15]. As this combined chemotherapy regimen was greatly effec-
tive for recurrent/metastatic HNSCC, clinical studies of weekly PTX
plus cetuximab should be conducted to investigate its efﬁcacy for
metastatic ACC. We  have high expectations for this combined reg-
imen, which may  give the treatment option for initially aggressive
metastatic ACC of the salivary gland and/or its symptoms.Conﬂict of interest statement
The  authors have no conﬂicts of interest to declare.
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